Perfil
Alan Tyndall is the founder of Magenta Therapeutics, Inc. (2015).
He is currently a Professor-Emeritus at the University of Basel (since 1991) and serves as Secretary at the World Scleroderma Foundation.
Mr. Tyndall received his undergraduate degree from the University of Sydney in 1972.
Mr. Tyndall is also the founder of Iterata AG.
Cargos activos de Alan Tyndall
| Empresas | Cargo | Inicio |
|---|---|---|
| University of Basel | Corporate Officer/Principal | 01/01/1991 |
| World Scleroderma Foundation | Secretario Corporativo | - |
| Iterata AG | Fundador | - |
Antiguos cargos conocidos de Alan Tyndall.
| Empresas | Cargo | Fin |
|---|---|---|
| MAGENTA THERAPEUTICS | Fundador | - |
Formación de Alan Tyndall.
| The University of Sydney | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
| World Scleroderma Foundation | |
| Iterata AG |
- Bolsa de valores
- Insiders
- Alan Tyndall
